Skip to main content

Table 1 Patient characteristics

From: Cardiovascular disease risk profiles in inflammatory joint disease entities

Variables IJD (n = 3517) RA (n = 1961) axSpA (n = 835) PsA (n = 721) p
Female, n (%) 2046 (58.2) 1389 (70.8) 293 (35.1) 364 (50.5) <0.001
Age in years, mean ± SD 55.1 ± 11.6 59.1 ± 11.2 48.4 ± 9.6 52.0 ± 10.0 <0.001
 Age 30 to <45 years, n (%) 774 (22.0) 245 (12.4) 338 (40.5) 191 (26.5) -
 Age 45 to <60 years, n (%) 1485 (42.2) 729 (37.2) 385 (46.1) 371 (51.5) -
 Age 60 to ≤80 years, n (%) 1258 (35.8) 987 (50.3) 112 (13.4) 159 (22.1) -
Working/student, n (%) 1755 (52.4) 806 (43.0) 543 (68.4) 406 (59.9) <0.001
Education in years, mean ± SD 12.9 ± 3.3 12.4 ± 3.3 13.8 ± 3.1 13.3 ± 3.0 <0.001
Conventional CVD risk factors
 Total cholesterol (mmol/l), mean ± SD 5.37 ± 1.1 5.38 ± 1.09 5.29 ± 1.05 5.41 ± 1.07 0.065
 Triglycerides (mmol/l), median (IQR) 1.30 (0.94, 1.86) 1.24 (0.93, 1.74) 1.34 (0.91, 1.92) 1.43 (1.00, 2.16) <0.001
 LDL-c (mmol/l), mean ± SD 3.29 ± 0.97 3.27 ± 0.97 3.29 ± 0.96 3.37 ± 0.97 0.056
 HDL-c (mmol/l), mean ± SD 1.56 ± 0.51 1.64 ± 0.52 1.47 ± 0.48 1.45 ± 0.46 <0.001
 Body mass index (kg/m2), mean ± SD 26.5 ± 4.6 26.1 ± 4.5 26.4 ± 4.3 28.0 ± 4.9 <0.001
 Systolic BP (mmHg), mean ± SD 132.0 ± 17.1 132.1 ± 17.3 129.8 ± 16.7 133.9 ± 16.9 <0.001
 Diastolic BP (mmHg), mean ± SD 80.7 ± 9.5 80.0 ± 9.2 80.9 ± 10.1 82.4 ± 9.4 <0.001
Rheumatic disease related variables
 RF IgM+, n (%) - 787 (66.5) - - -
 ACPA+, n (%) - 1066 (77.3) - - -
 HLA-B27+, n (%) - - 445 (85.6) - -
Disease duration in years, median (IQR) 8.4 (3.8, 16.6) 8.3 (4.0, 15.4) 10.3 (3.8, 20.8) 7.6 (3.1, 15.3) <0.001
ESR (mm/h), median (IQR) 9 (5, 17) 10 (5, 19) 7 (3, 15) 8 (4, 16) 0.095
CRP (mg/l), median (IQR) 3 (1, 5) 3 (1, 6) 3 (1, 5) 3 (1, 5) <0.001
DAS28 (ESR), mean ± SD - 2.59 ± 1.24 - 2.51 ± 1.28 -
 Remission (<2.6), n (%) - 912 (55.2) - 313 (55.9) -
 Low disease activity (2.6 to <3.2), n (%) - 273 (16.5) - 90 (16.1) -
 Moderate disease activity (3.2 to ≤5.1), n (%) - 405 (24.5) - 137 (24.5) -
 High disease activity (>5.1), n (%) - 63 (3.8) - 20 (3.6) -
ASDAS (CRP), median (IQR) - - 1.59 (1.04, 2.53) 1.54 (0.99, 2.31) -
 Inactive (<1.3), n (%) - - 236 (37.8) 182 (40.4) -
 Moderate (1.3 to <2.1), n (%) - - 165 (26.4) 129 (28.6) -
 High (2.1 to ≤3.5), n (%) - - 184 (29.4) 112 (24.8) -
 Very high (>3.5), n (%) - - 40 (6.4) 28 (6.2) -
BASDAI, median (IQR) - - 1.29 (0.25, 4.13) 1.09 (0.26, 3.73) -
Antirheumatic medication, current use
 Glucocorticoids, n (%) 641 (18.2) 575 (29.3) 17 (2.0) 49 (6.8) <0.001
 Methotrexate, n (%) 1451 (41.3) 1100 (56.1) 54 (6.5) 297 (41.2) <0.001
 Other sDMARDs, n (%) 1925 (54.7) 1462 (74.6) 88 (10.5) 375 (52.0) <0.001
 bDMARDs, n (%) 1750 (49.8) 848 (43.2) 518 (62.0) 384 (53.3) <0.001
  1. ACPA anti-cyclic citrullinated peptide antibodies, ASDAS-CRP Ankylosing Spondylitis Disease Activity SCORE using CRP, axSpA axial spondyloarthtis, BASDAI Bath ankylosing spondylitis disease activity index, BP blood pressure, BMI body mass index, CVD cardiovascular disease, CRP C-reactive protein, DAS28-ESR Disease Activity Score using 28 joint-ESR, ESR erythrocyte sedimentation rate, HDL-c high-density lipoprotein-cholesterol, HLA-B27 histocompatibility antigen HLA-B27, IJD inflammatory joint diseases, LDL-c low-density lipoprotein-cholesterol, PsA Psoriatic arthritis, RA rheumatoid arthritis, RF rheumatoid factor, sDMARDs and bDMARDs synthetic and biologic disease-modifying antirheumatic drugs